Analysts predict that Amedisys Inc (NASDAQ:AMED) will post $0.79 earnings per share (EPS) for the current quarter, Zacks reports. Six analysts have made estimates for Amedisys’ earnings. The lowest EPS estimate is $0.72 and the highest is $0.93. Amedisys reported earnings per share of $0.56 during the same quarter last year, which suggests a positive year-over-year growth rate of 41.1%. The company is expected to issue its next quarterly earnings results on Tuesday, November 6th.

According to Zacks, analysts expect that Amedisys will report full-year earnings of $3.41 per share for the current year, with EPS estimates ranging from $3.37 to $3.60. For the next financial year, analysts forecast that the business will post earnings of $3.87 per share, with EPS estimates ranging from $3.66 to $4.20. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Amedisys.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, July 31st. The health services provider reported $1.00 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The business had revenue of $411.60 million during the quarter, compared to analysts’ expectations of $403.62 million. During the same quarter in the prior year, the business earned $0.62 earnings per share.

AMED has been the topic of a number of recent analyst reports. Royal Bank of Canada upped their price objective on Amedisys to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 3rd. Cantor Fitzgerald initiated coverage on Amedisys in a report on Thursday, September 13th. They set a “neutral” rating and a $117.00 price objective on the stock. Robert W. Baird upped their price objective on Amedisys from $67.00 to $72.00 and gave the stock a “neutral” rating in a report on Tuesday, June 5th. Stephens reaffirmed a “hold” rating and set a $78.00 price objective on shares of Amedisys in a report on Tuesday, June 5th. Finally, Bank of America raised Amedisys from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $88.00 to $97.00 in a report on Tuesday, July 3rd. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $86.46.

Shares of AMED stock opened at $118.55 on Friday. Amedisys has a 1-year low of $45.60 and a 1-year high of $126.30. The firm has a market cap of $3.77 billion, a P/E ratio of 53.64, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30.

In other Amedisys news, insider David B. Pearce sold 398 shares of the company’s stock in a transaction on Wednesday, July 25th. The stock was sold at an average price of $94.18, for a total value of $37,483.64. Following the sale, the insider now owns 12,216 shares of the company’s stock, valued at $1,150,502.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of AMED. Rhumbline Advisers grew its holdings in Amedisys by 2.5% in the first quarter. Rhumbline Advisers now owns 66,630 shares of the health services provider’s stock valued at $4,020,000 after purchasing an additional 1,621 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Amedisys in the first quarter valued at $123,000. Xact Kapitalforvaltning AB acquired a new stake in Amedisys in the first quarter valued at $257,000. Mount Yale Investment Advisors LLC acquired a new stake in Amedisys in the first quarter valued at $151,000. Finally, Atria Investments LLC acquired a new stake in Amedisys in the second quarter valued at $233,000. 93.31% of the stock is currently owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Recommended Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.